Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Escaped zebra captured near Seattle after gallivanting around Cascade mountain foothills for daysANDREW PIERCE: Don't mention the Tories! How DarlingtonSouth Sudan removes newly imposed taxes that had triggered suspension of UN food airdropsHow major US stock indexes fared Friday, 5/3/2024Family tree reveals Taylor Swift is a descendant of French King Louis XIVIOC imposes 15Kate Hudson makes TV debut performing as singer on The Tonight Show Starring Jimmy FallonKentucky Derby to remain on NBC through 2032 in extension with Churchill DownsBayern left back Guerreiro sustains injury before Real Madrid in Champions League semifinalKhloe Kardashian shows off her curves in form